Two-Year Safety and Efficacy of Ranibizumab 0.5 mg in Diabetic Macular Edema
- 30 May 2013
- journal article
- research article
- Published by Elsevier BV in Ophthalmology
- Vol. 120 (10), 2004-2012
- https://doi.org/10.1016/j.ophtha.2013.02.019
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Ranibizumab for Diabetic Macular EdemaOphthalmology, 2012
- New approaches for the treatment of diabetic macular oedema: recommendations by an expert panelEye, 2012
- Expanded 2-Year Follow-up of Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular EdemaOphthalmology, 2011
- The RESTORE StudyOphthalmology, 2011
- Two-Year Outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) StudyOphthalmology, 2010
- Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study)Diabetes Care, 2010
- Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular EdemaOphthalmology, 2010
- Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) StudyOphthalmology, 2009
- DEVELOPMENT OF RANIBIZUMAB, AN ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIGEN BINDING FRAGMENT, AS THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATIONRetina, 2006
- Photocoagulation for Diabetic Macular EdemaAmerican Journal of Ophthalmology, 1985